These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms. Xu C; Wang A; Geng K; Honnen W; Wang X; Bruiners N; Singh S; Ferrara F; D'Angelo S; Bradbury ARM; Gennaro ML; Liu D; Pinter A; Chang TL Viruses; 2021 May; 13(6):. PubMed ID: 34064066 [TBL] [Abstract][Full Text] [Related]
4. Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 spike interaction with hACE2. Ssenyange G; Kerfoot M; Zhao M; Farhadian S; Chen S; Peng L; Ren P; Dela Cruz CS; Gupta S; Sutton RE Cell Rep Methods; 2022 Jul; 2(7):100252. PubMed ID: 35757815 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19). Nayak SK Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2. Rowland R; Brandariz-Nuñez A Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876 [TBL] [Abstract][Full Text] [Related]
7. Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples. Meyrath M; Szpakowska M; Plesseria JM; Domingues O; Langlet J; Weber B; Krüger R; Ollert M; Chevigné A; Methods Enzymol; 2022; 675():351-381. PubMed ID: 36220277 [TBL] [Abstract][Full Text] [Related]
8. Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains. Qing E; Kicmal T; Kumar B; Hawkins GM; Timm E; Perlman S; Gallagher T mBio; 2021 Aug; 12(4):e0159021. PubMed ID: 34340537 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. Sholukh AM; Fiore-Gartland A; Ford ES; Miner MD; Hou YJ; Tse LV; Kaiser H; Zhu H; Lu J; Madarampalli B; Park A; Lempp FA; St Germain R; Bossard EL; Kee JJ; Diem K; Stuart AB; Rupert PB; Brock C; Buerger M; Doll MK; Randhawa AK; Stamatatos L; Strong RK; McLaughlin C; Huang ML; Jerome KR; Baric RS; Montefiori D; Corey L J Clin Microbiol; 2021 Sep; 59(10):e0052721. PubMed ID: 34288726 [TBL] [Abstract][Full Text] [Related]
10. The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2. Yu F; Liu X; Ou H; Li X; Liu R; Lv X; Xiao S; Hu M; Liang T; Chen T; Wei X; Zhang Z; Liu S; Liu H; Zhu Y; Liu G; Tu T; Li P; Zhang H; Pan T; Ma X mBio; 2024 Aug; 15(8):e0108824. PubMed ID: 38953634 [TBL] [Abstract][Full Text] [Related]
11. Engineering a NanoBiT biosensor for detecting angiotensin-converting enzyme-2 (hACE2) interaction with SARS-CoV-2 spike protein and screening the inhibitors to block hACE2 and spike interaction. Lin CH; Yang XR; Lin MW; Chang HJ; Lee CH; Lin CS Biosens Bioelectron; 2024 Nov; 263():116630. PubMed ID: 39102773 [TBL] [Abstract][Full Text] [Related]
12. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194 [TBL] [Abstract][Full Text] [Related]
13. An easy method for developing fusion enabled SARS-CoV2 virus fusion mimic (SCFM), bypassing the need of Bio Safety Level (BSL) facility. Das A; Dutta S; Sharma D; Pal A; Ganguli N; Majumdar SS Bioengineered; 2021 Dec; 12(1):4407-4419. PubMed ID: 34436976 [TBL] [Abstract][Full Text] [Related]
16. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor. Kim YS; Chung HS; Noh SG; Lee B; Chung HY; Choi JG Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445310 [TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP mBio; 2021 Mar; 12(2):. PubMed ID: 33785634 [TBL] [Abstract][Full Text] [Related]
18. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation. Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407 [TBL] [Abstract][Full Text] [Related]
20. Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants. Han P; Su C; Zhang Y; Bai C; Zheng A; Qiao C; Wang Q; Niu S; Chen Q; Zhang Y; Li W; Liao H; Li J; Zhang Z; Cho H; Yang M; Rong X; Hu Y; Huang N; Yan J; Wang Q; Zhao X; Gao GF; Qi J Nat Commun; 2021 Oct; 12(1):6103. PubMed ID: 34671049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]